A Study of CDX-0159 in Patients With Prurigo Nodularis

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 8, 2021

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions
Prurigo Nodularis
Interventions
BIOLOGICAL

CDX-0159

administered intravenously

DRUG

Normal saline

administered intravenously

Trial Locations (17)

10128

Markowitz Medical/Optiskin, New York

33125

University of Miami, Dermatology Clinical Trials Unit, Miami

48084

Revival Research Institute, LLC, Troy

73071

Central Sooner Research, Norman

77004

Center for Clinical Studies, LTD.LLP, Houston

85284

Desert Sky Dermatology, Tempe

87131

University of New Mexico, Albuquerque

Unknown

Charité Centrum für Innere Medizin und Dermatologie, Institute of Allergology (IFA), Berlin

Katholisches Klinikum Bochum gGmbH, Dermatologische Studienambulanz, Bochum

Universitatsklinikum Carl Gustav Carus Dresden, Klinik und Poliklinik fur Dermatologie, Dresden

Universitätsklinikum Frankfurt Klinik für Dermatologie, Venerologie und Allergologie Klinische Forschung, Frankfurt

Universitätsklinikum Erlangen Hautklinik, Mainz

Universitätsmedizin der Johannes Gutenberg-Universität Mainz Hautklinik, Clinical Research Center, Mainz

Universitaetsklinikum Muenster (UKM) - Klinik für Hautkrankheiten, Münster

MT Medic Specjalistyczna Praktyka Lekarska, Krosno

IP Clinic Sp. z o.o., Lodz

Centrum Medyczne Ginemedica, Wroclaw

Sponsors
All Listed Sponsors
lead

Celldex Therapeutics

INDUSTRY

NCT04944862 - A Study of CDX-0159 in Patients With Prurigo Nodularis | Biotech Hunter | Biotech Hunter